Cirius Therapeutics to Present Innovative Data on CIR-0602K at CVCT Forum 2025 Cirius Therapeutics reveals compelling results on CIR-0602K's cardiometabolic benefits at CVCT Forum 2025, showcasing innovative therapies.

Cirius Therapeutics to Present Innovative Data on CIR-0602K at CVCT Forum 2025 #USA #Washington #Cirius_Therapeutics #cardiometabolic #CIR-0602K

Cirius Therapeutics' Breakthrough Data on CIR-0602K with Tirzepatide at ObesityWeek 2025 Newly unveiled data from Cirius Therapeutics highlights the synergistic effects of CIR-0602K combined with Tirzepatide, promising enhanced weight loss and metabolic benefits.

Cirius Therapeutics' Breakthrough Data on CIR-0602K with Tirzepatide at ObesityWeek 2025 #USA #Grand_Rapids #tirzepatide #Cirius_Therapeutics #CIR-0602K

Cirius Therapeutics and Breakthrough T1D Partner for Groundbreaking Phase 2 Study of CIR-0602K Cirius Therapeutics teams up with Breakthrough T1D and UVA Health to investigate CIR-0602K, a promising new therapy for Type 1 Diabetes.

Cirius Therapeutics and Breakthrough T1D Partner for Groundbreaking Phase 2 Study of CIR-0602K #USA #New_York #Cirius_Therapeutics #T1D #CIR-0602K

Cirius Therapeutics to Reveal Innovative Data on 0602K and Tirzepatide at ADA 2025 Scientific Sessions Cirius Therapeutics will present its groundbreaking findings on the combination of 0602K and tirzepatide at the upcoming ADA 2025 Scientific Sessions, showcasing advancements in treating insulin resistance.

Cirius Therapeutics to Reveal Innovative Data on 0602K and Tirzepatide at ADA 2025 Scientific Sessions #United_States #Chicago #tirzepatide #Cirius_Therapeutics #0602K

Cirius Therapeutics To Showcase Innovations in Metabolic Treatment at WuXi Forum Discover the latest advancements in metabolic medications as Cirius Therapeutics presents its innovative therapy, azemiglitazone, at the esteemed WuXi Global Forum.

Cirius Therapeutics To Showcase Innovations in Metabolic Treatment at WuXi Forum #United_States #San_Francisco #diabetes #Cirius_Therapeutics #azemiglitazone